Amgen (AMGN) Capital Expenditures (2009 - 2026)

Amgen (AMGN) has reported Capital Expenditures for 18 consecutive years, with $712.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 73.24% year-over-year to $712.0 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 69.07% YoY), while the FY2025 annual figure was $1.9 billion, up 69.53% from the prior year.
• Capital Expenditures came in at $712.0 million for Q1 2026 at Amgen, up from $642.0 million in the prior quarter.
• The five-year high for Capital Expenditures was $712.0 million in Q1 2026, with the low at $160.0 million in Q3 2022.
• Average Capital Expenditures over 5 years is $336.1 million, with a median of $271.0 million recorded in 2023.
• Across the five-year window, Capital Expenditures plunged 33.88% in 2022 and soared 81.05% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $340.0 million in 2022, then decreased by 26.76% to $249.0 million in 2023, then jumped by 49.0% to $371.0 million in 2024, then surged by 73.05% to $642.0 million in 2025, then increased by 10.9% to $712.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $712.0 million, $642.0 million, and $436.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.